Characterization of β-lactam antibiotic-induced vancomycin-resistant MRSA (BIVR) in a patient with septicemia during long-term vancomycin administration

Yamaguchi, Yoshio; Hanaki, Hideaki; Yanagisawa, Chie; Ikeda-Dantsuji, Yurika; Hasegawa, T.; Yazaki, Harunori; Sugahara, Keiko; Yanagisawa, Takashi; Kawajiri, Hiroki; Sato, Sae; Ishizaki, Aki; Tachihara-Sato, Rika; Takahashi, Yui; Ono, Taro; Kageyama, Yoichi; Kawaguchi, Tomohumi; Tamura, Akihiko; Hagane, Kazuhiko; Sunakawa, Keisuke

doi:10.1007/s10156-009-0703-y

Cited by 7 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, intravenous fosfomycin has been administered in critically ill patients with sepsis or nosocomial-acquired infections due to MRSA, vancomycin-resistant Enterococcus, and MDR Gramnegative bacteria, especially carbapenem-resistant K. pneumoniae, in combination with other antibiotics, due to its unique mechanism of action and its protective effect against nephrotoxicity induced by aminoglycosides or colistin. [64][65][66] Michalopoulos et al 65 examined the effectiveness and safety of fosfomycin in critically ill patients suffering from ICU-acquired infections due to carbapenem-resistant K. pneumoniae. They concluded that fosfomycin may be considered an alternative for the treatment of infections due to carbapenem-resistant K. pneumoniae in adult patients, especially in combination with other antibiotics.…”

Section: Intravenous Fosfomycin In Clinical Usementioning

confidence: 99%

See 1 more Smart Citation

The revival of fosfomycin

Michalopoulos

Livaditis

Gougoutas

2011

International Journal of Infectious Diseases

336

296

View full text Add to dashboard Cite

Fosfomycin, originally named phosphonomycin, was discovered in Spain in 1969. There are three forms of fosfomycin: fosfomycin tromethamine (a soluble salt) and fosfomycin calcium for oral use, and fosfomycin disodium for intravenous use. Fosfomycin is a bactericidal antibiotic that interferes with cell wall synthesis in both Gram-positive and Gram-negative bacteria by inhibiting the initial step involving phosphoenolpyruvate synthetase. It has a broad spectrum of activity against a wide range of Gram-positive and Gram-negative bacteria. It is highly active against Gram-positive pathogens such as Staphylococcus aureus and Enterococcus, and against Gram-negative bacteria such as Pseudomonas aeruginosa and Klebsiella pneumoniae. Its unique mechanism of action may provide a synergistic effect to other classes of antibiotics including beta-lactams, aminoglycosides, and fluoroquinolones. Oral fosfomycin is mainly used in the treatment of urinary tract infections, particularly those caused by Escherichia coli and Enterococcus faecalis. Intravenous fosfomycin has been administered in combination with other antibiotics for the treatment of nosocomial infections due to multidrug-resistant (MDR) Gram-positive and Gram-negative bacteria. Fosfomycin has good distribution into tissues, achieving clinically relevant concentrations in serum, kidneys, bladder wall, prostate, lungs, inflamed tissues, bone, cerebrospinal fluid, abscess fluid, and heart valves. Fosfomycin is well tolerated, with a low incidence of adverse events. Further randomized controlled trials are needed in order to evaluate the efficacy of intravenous fosfomycin for the management of nosocomial infections due to MDR pathogens.

show abstract

Section: Intravenous Fosfomycin In Clinical Usementioning

confidence: 99%

“…All studies dealing with the curative use of intravenous fosfomycin in adult patients are presented in Table 1. 33,65,66,[69][70][71][72][73][74][75][76][77][78][79][80][81][82][83][84]…”

Section: Intravenous Fosfomycin In Clinical Usementioning

confidence: 99%

The revival of fosfomycin

Michalopoulos

Livaditis

Gougoutas

2011

International Journal of Infectious Diseases

336

296

View full text Add to dashboard Cite

show abstract

“…Fosfomycin has a broad spectrum of activity against a wide range of Gram-positive and Gram-negative bacteria. Its unique mechanism of action may provide a synergistic effect to other antibiotics including beta-lactams, aminoglycosides, and fluoroquinolones [20][21][22] Recently, intravenous fosfomycin has been administered in critically ill patients with sepsis or nosocomial-acquired infections due to MRSA, vancomycin-resistant Enterococcus, and MDR Gram-negative bacteria, especially carbapenem-resistant Klebsiella pneumoniae, in combination with other antibiotics, due to its unique mechanism of action and its protective effect against nephrotoxicity induced by aminoglycosides or colistin [23][24][25]. Rationale for combining fosfomycin with a second antimicrobial agent is to prevent the emergence of fosfomycin resistant strains.…”

Section: Discussionmentioning

confidence: 99%

Treatment of Methicillin-Resistant Staphylococcus Aureus (Mrsa) Sepsis With Combination of Fosfomycin and Amikacin in a Patient With Scald-Burn Injury

Putra

Saputro

2018

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objective: Thus, this case report assesses the efficacy combination of fosfomycin and amikacin in the management of MRSA infection in a burn patient.Case Report: A 31-year-old male was transferred to the burn center for definitive treatment. Initially, the patient was treated with ceftazidime injection as empiric antibiotic one gram three times daily, but the patient became sepsis during the treatment. Blood specimen was taken and Methicilin Resistant Staphylococcus aureus (MRSA) was isolated from this culture. The patient was isolated and based on antibiotic susceptibility, the patient was started on fosfomycin 2 gram IV twice daily for first seven days, and after that fosfomycin was combined with amikacin IV 500 mg once daily. After administration of these antibiotics, a rapid clinical improvement was observed with the patient, leucocytosis did not occur and blood culture was negative. The patient completed a total of 14 days of fosfomycin and 8 days of amikacin therapy.Conclusion: The synergistic combination of fosfomycin with amikacin, may be useful alternative treatment option for sepsis related Methicilin- Resistant Staphylococcus aureus (MRSA) in burn injury. Further research is also needed to clarify effectiveness of fosfomycin and amikacin to treat MRSA infection in burn patient.

show abstract

“…[1][2][3] In recent years, the rate of IV fosfomycin usage has increased in critically ill patients with sepsis or hospital-acquired infec-tions due to MDR Gram-negative bacteria, especially carbapenem-resistant Klebsiella pneumoniae. [4][5][6] Our study aimed to investigate the factors affecting the survival rate and mortality of IV fosfomycin, which is increasingly used in our hospital due to carbapenem-resistant gram-negative bacterial infections.…”

Section: Introductionmentioning

confidence: 99%

Factors Affecting Mortality in Resistant Gram-negative Infections Developed in Patients Followed in the Intensive Care Unit and Treated with Fosfomycin

Işık¹

2023

Comprehensive Med

View full text Add to dashboard Cite

Objective: Our study aimed to investigate the survival rates and factors affecting mortality in Gram-negative infections treated with intravenous (IV) fosfomycin. Materials and Methods:Patients with microbiologically proven infections in our hospital's intensive care unit (ICU) and who were treated with IV fosfomycin between 2019 and 2021 were included in our study. Demographic characteristics of the patients and initiation of treatment sequential organ failure assessment (SOFA) score, indications for fosfomycin usage, microbiological and clinical response to treatment, and outcome status of the patients were screened. Results:Of the 96 patients included in the study, 58% (n=56) were male. The survival rate of the patients who received fosfomycin treatment was 27% (n=26). There was no statistically significant difference between the patient's age, gender, and comorbidities according to the outcome. The disease in which fosfomycin treatment was used the most was pneumonia (87%), and the most treated bacteria were Klebsiella pneumoniae (84%). No statistically significant correlation was found between the outcome status of the patients and the site of infection. However, there was a statistically significant relationship regarding initiation of the treatment SOFA score, type of concomitant antibiotic, clinical response after 72 h, microbiological response at the end of treatment, development of acute renal failure, and development of thrombocytopenia. Conclusion:Care should be taken when administering combined treatments with fosfomycin to patients followed in the ICU and infected with multi-drug resistant Gram-negative infections. Treatment options are limited in this patient group, which has high mortality rates despite treatment. Our study investigated the parameters that can be used to predict treatment response to fosfomycin. It was thought that it would be beneficial to start the treatment according to these parameters when treating this patient group.

show abstract

Characterization of β-lactam antibiotic-induced vancomycin-resistant MRSA (BIVR) in a patient with septicemia during long-term vancomycin administration

Cited by 7 publications

References 17 publications

The revival of fosfomycin

The revival of fosfomycin

Treatment of Methicillin-Resistant Staphylococcus Aureus (Mrsa) Sepsis With Combination of Fosfomycin and Amikacin in a Patient With Scald-Burn Injury

Factors Affecting Mortality in Resistant Gram-negative Infections Developed in Patients Followed in the Intensive Care Unit and Treated with Fosfomycin

Contact Info

Product

Resources

About